Tianshui Zhongxing Bio-Technology reports strong Q3 profit jump, revenue growth

Tianshui Zhongxing Bio-Technology (SZSE:002772) reported a robust performance for the third quarter of 2025, with net profit attributable to shareholders increasing by 130.51% year-on-year to 204.3m yuan. Basic earnings per share rose by 141.79% to 0.5450 yuan, driven by higher mushroom product sales and reduced financial costs. Total revenue for the period reached 1.48bn yuan, a 4.16% increase.

The company's total assets grew by 5.88% to 6.55bn yuan. Prepayments increased by 82.86% to 41.28m yuan, and other receivables surged by 136.07% to 6.05m yuan, mainly due to increased business scale and guarantee deposits. Long-term borrowings rose by 43.77% to 1.52bn yuan to fund new projects and operations.

In operational developments, the company amended its Articles of Association, with the industrial and commercial registration change finalized on October 15, 2025. Additionally, Tianshui Zhongxing Bio-Technology approved and initiated a 2025 stock option incentive plan, with the first grant to eligible employees approved on October 15, 2025.